chrisvoncsefalvay/vaers-outcomes huggingface dataset:
allergic to vaccine; Initial information received on 23-Nov-2020 regarding an unsolicited valid non-serious case from a patient via social media.  This case involves a patient of unknown demographics who was allergic to them (allergy to vaccine), while the patient received vaccine Influenza Vaccine.  The patient's medical history, past medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   On an unknown date, the patient received an unknown dose of suspect influenza vaccine produced by unknown manufacturer (lot number, route, administration site and expiry date were not reported) for prophylactic vaccination.  On an unknown date, the patient was allergic to them (allergy to vaccine), (unknown latency) following the administration of influenza vaccine.  No relevant laboratory test was reported.  It was not reported if the patient received a corrective treatment.  The event outcome was unknown at the time of reporting.  There will be no information available on the batch number for this case.
Dizziness; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP). Other Case identifier(s): NVSC2021US176568_NS.  A 60-year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 60 years as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DIZZINESS (non-serious), outcome "unknown", described as "Dizziness".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient received flu shot 10/06/14.  Patient presented back at pharmacy 11/13/14 with complaint of dull persistent pain in back of immunized arm.  According to patient account, vaccine suspected to be given by subcutaneous route in back of arm instead of deltoid muscle..
Dizziness, Headache, Myalgia, Fever, sore arm Narrative:
Mild soreness the night she rcvd her 1st dose on 3/10/2021, soreness cleared up the next day. Caller mentioned that approx. 9 days after rcvding her vaccine on 3/19/2021 she noticed her left deltoid area had a pink coloration that is the size of a tanagrine (no pain, swelling or soreness) and as a precaution she took otc Benadryl the morning of 3/20/2021 and applied hydrocortisone cream on the area. Caller also stated it was a possiblity that she had gotten bitten by an insect while working in her yard on 3/19/2021.
8 x 4 cm area of erythema (L) upper thigh, some induration in the center, warm to touch and tender. Cold compress.
Information has been received from a health professional concerning a 21 year old female with no past medical history or allergies who in "childhood" and in 2/01 was vaccinated with the 1st and 2nd dose of MMRII, respectively. There was no concomitant therapy. In 8/01, the pt had titers drawn which revealed that the mumps titer was .97 which was considered to be equivocal. It was also reported that the pt had a lack of sero-conversion. The measles and rubella titers were positive. Additional information has been requested.
34 y/o received HEP B vaccine 7-30-10. C/o small ant. of swelling to throat, little difficult breathing, tension to lateral sides of neck, H.A., dizziness, and states at night pain to (R) side-back of head also feels like something is "shaking" inside of head. Also feels unbalanced. Went to ER given x2 tablets for H.A. and ordered to see MD Monday.
After normal reaction for about seven hours, there was then the onset of severe pain in the left arm where the shot was given. The pain was greater than what had been experienced even when this patient had dengue fever. There was also paralysis of the left arm which was stuck to the side of the body. Three doses of hydrocodone over the next eight hours relieved the pain, and the paralysis gradually diminished. After three more uncomfortable days the patient was almost back to normal and continuing to improve. Discussions with hospital where this was administered and two other clinics that do numerous similar vaccines indicated no other cases of this serious a reaction. The patient is of course curious if there is a form of pneumonia vaccine they can safely take in the future. Because they certainly won't repeat this one. The vaccine that was given pneumococcal polysaccharide 23 Valent.
Day three mild swollen tongue that lasted 5 hours,  day five mild swollen upper right lip that lasted 5 hours, day six moderate swollen  left face/cheek that lasted 24 hours, day seven swollen left hand/wrist that was extremely itchy that lasted 24 hours and counting.
Breakthrough case admission after 2nd vaccine 2/1921 Pfizer Lot# EN6200 3/11/21 Pfizer Lt# EN6199
After vaccine and nearly out of the office. Patient had syncopal event. May have hit back of head/neck. Not witnessed. Patient brought to room and laid down. BP and heart rate was monitored. Given juice to drink. Patient felt sore on right upper neck area. No bruising or swelling of head or neck. Head and neck non tender to palpation. Neck with full ROM. Patient recovered with rest and discharged home.
Very Rapid pulse, fever, malaise, Missed 1 week of work in bed. Heart Rate still fast at bed time often
This spontaneous report as received from a registered nurse refers to a 17 years old patient. The patient was vaccinated with  (Merck) PROQUAD (lot number not provided) on 30-NOV-2012. No other co-suspects were reported. No concomitant medications were reported. No adverse symptoms reported. It was unspecified if the patient had sought medical attention. Additional information has been requested.
Patient received vaccine at 11:04. At 11:08 patient was checked on during rounds of monitoring for s/s of reaction and she stated that her hr feels like it was elevated, lips were tingling and the lower right part of her face was numb.  Vitals were taken at this time BP was 110/68 HR 102. Patient was given Benadryl 50mg IM at this time x1 and monitored for 10 more minutes. Husband came and picked the patient up due to we told her she was unable to drive.
Skin around injection site bright red and warm to touch. Onset within 1 hr of injection w/ peak redness noted at 48 hr. At its peak, redness measured 15 cm. Duration 5 days.  Patient sought medical attention through her PCP. Was advised by PCP was "allergic reaction". No treatment rendered.
Pharmacist calls to report female patient received 1st dose 11/30/2022.  2nd dose 9/5/2023.  GARDASIL 9.  No further AE.  No PQC  See request case#02465379; No further AE; This spontaneous report has been received from a pharmacist, regarding a 35-years-old patent of unknown gender. The patient's pertinent medical history, previous drug reactions or allergies and concomitant medications were not reported.  On 30-NOV-2022 and 05-SEP-2023, the patient was vaccinated with the first and second dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) injection, as prophylaxis (strengths, doses, routes and anatomical locations of administration, lot numbers and expiration dates were not reported) (Inappropriate schedule of vaccine administered).  No additional adverse event was reported.
vaccination administered on 2/4/23 after being thawed on 11/5/2022. Per manufacturer, vaccine should be discarded after thawed for 30-days. Vaccine given outside of these parameters. Patient did not report any adverse reactions/symptoms at this time.
This spontaneous report was received from a male physician of unknown age and via a company representative reporting on himself. Concurrent conditions and medical history were not report4ed. On an unknown date, the physician was vaccinated with a dose of ZOSTAVAX (lot number, expiration date, dose and route were not reported. Concomitant medications were not reported. The physician reported that he developed herpes zoster reported as 'shingles and post herpetic neuralgia" on an unspecified date after receiving the ZOSTAVAX. No shingles rash was currently present, however, the physician still experienced transient post herpetic neuralgia pain in the eyes. The outcome of herpes zoster was reported as not recovered. The physician did not assess the relatedness of ZOSTAVAX to herpes zoster. Additional information has been requested.
24 hours post vax, the pt developed hives/urticaria. Pt went to ER and was given Benadryl IM and sent home on oral Benadryl. Symptoms resolved completely in 2 days.
Extreme Hair Loss; This is a spontaneous report from a contactable consumer (patient, self-reported). A 58-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number: EM9810 STEHS and expiry date was not reported), via an unspecified route of administration, in Arm Left, on 06Feb2021 at 11:45 PM (age at vaccination: 58 years), as a single dose for COVID-19 immunization at school or student health clinic. The patient was not pregnant at the time of vaccination. The patient's medical history included high B/P, high cholesterol, and kidney donor. The patient did not have any known allergies. Concomitant medications included unspecified medications. The patient did not received any other vaccine in four weeks. The patient was not diagnosed with COVID prior vaccination. The patient was not tested for COVID post vaccination. On 22Feb2021 at 07:00 AM, the patient experienced extreme hair loss. The patient did not receive any treatment for the event. Outcome of the event was unknown.  Follow-up attempts completed. No further information expected.
was planning to visit family soon and went to get a COVID test today. Unexpectedly, the COVID test returned positive. She has not had any fevers, chills, shortness of breath, or cough.
Site: Itching at Injection Site-Mild, Systemic: Allergic: Itch (specify: facial area, extremeties)-Mild, Additional Details: pt w/ slight itching in arm surrounding inj site shortly following 2nd dose in series.  prior to this vax, pt alerted immunizing tech and pharm that she experienced arm swelling and itchieness after initial dose as well.  as this has now been frequently reported, and does not qualify as a severe allergic reaction, pt was advised she may receive this second dose.  educated on vsafe, diphenhydramine dosing, and s/sx of severe anaphylactic rxn.  provided diphen 25mg PO x 1; left obs area w/ son
Patient received vaccine at 11:27 AM and was observed for reaction until 11:44 AM.   Patient returned to the Vaccine Clinic at 13:03 PM and reported that she was itching all over her body and her lower extremities were "blotchy".  Patient was assessed by the Observation RN, who took her to a private space to examine her skin, stating that the patient had blotchy area's on her lower extremities, but were not raised not raised like hives and no rash was present.  Patient refused Benadryl.  Employee Health Nurse was notified for patient follow-up.
This spontaneous report was received from a other nurse regarding a patient of unknown age and gender. The patient's medical history, current conditions and concomitant medications were not reported. On an unknown date, the patient was vaccinated with improperly stored VARIVAX lot # M036272 and expiry date: 07-AUG-2018 (dose and route were not reported) for prophylaxis. The vaccine was exposed to a temperature range of 6 Fahrenheit to 14 Fahrenheit for 41 minutes. There was a previous excursion of the range 15 Fahrenheit to 46 Fahrenheit for 1 hour and 42 minutes. The call was because of a digital data logger. No adverse effect reported. No additional information was provided. No product quality complaint involved. This is one of the two reports from the same reporter. Sender's Comments: US-009507513-1708USA007128.
Intermittent numbness lasting approx. 30 mins, 3-4 times per day since 1/26/2015 of hands and feet, occasionally lower legs. Never had this before.
Initial and follow-up information has been received through the Merck pregnancy registry from a physician and a licensed vocational nurse (LVN) concerning a 19 year old female with a history of depression and anxiety.  The patient had a history of an elective termination of 1 previous pregnancy.  On 26-SEP-2007, the patient was vaccinated with her first dose of GARDASIL (Lot # 0530U).  Concomitant therapy included "CLONAZEPAK" (therapy unspecified).  Subsequently, the patient found out she was pregnant.  The patient's last menstrual period (LMP) was 02-OCT-2007, with an estimated delivery date of 09-JUL-2008.  The patient sought medical attention.  On 16-JUN-2008, the patient was treated with VISTARIL 50 mg, 1 every 6 hours PRN for anxiety.  During the pregnancy, the patient had complication of mild pregnancy induced hypertension (PIH).  On 02-JUL-2008, 39 weeks from LMP, the patient delivered a normal female infant with Apgar score of 9/9.  Additional information is not expected.
herpes zoster; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently 64 years old female patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications. In November 2016, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route not specified) for the long-term prevention of shingles and zoster-related conditions. On an unspecified date, the patient experienced herpes zoster. On an unspecified date, the patient was treated by a physician for herpes zoster. The outcome of the event herpes zoster was not reported. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).  Additional information has been requested.
Besides the expected pain at the vaccine arm area, the following morning I had what felt like seasonal allergies but much more severe than usual. Heavy sneezing, congestion, nasal passage swelling, headache. Symptoms lasted about 6 hours and then subsided after taking allergy medication (Claritin and Neodefrin) and naproxen for the headache and arm pain.
Lt-sided facial pain which evolved into dizziness, inc pain & asymetric pupils w/miosis of lt pupil; migraine; ptosis; Horner syndrome; double vision; lt lateral gaze; pending dx: Raeder's syndrome, trigeminal neuralgia, migraine; ANA pos;
This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (got the first dose of the Moderna vaccine on 01Apr2021 and has not got the second dose yet) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 008B21A) for COVID-19 vaccination. No Medical History information was reported. On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (got the first dose of the Moderna vaccine on 01Apr2021 and has not got the second dose yet). At the time of the report, PRODUCT DOSE OMISSION ISSUE (got the first dose of the Moderna vaccine on 01Apr2021 and has not got the second dose yet) had resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. No concomitant medications were reported. No treatment medications were reported.
Onset of fever 24 hrs post vaccine. Circular Erythema 9.25cm X 9.25cm noted on 2/1/14 at office visit.
The mother reports that there was no redness or heat at the injection site at the time of vaccination. However, after a few days, the child was unable to move his right arm. The mother took the child to the doctor. A surgical drainage was performed. Mom pointed to the an area near the child's armpit as the site of the surgical drainage procedure. This was reported to us for the first time on 8/27/2012 when the child was at our clinic again for an additional set of immunizations. Mom is not aware that any VAERS report was ever filed.
After getting vaccinated at 20 minutes I felt dizziness and tachycardia for about 1 minute. Do not notify the pharmacy because it relieves me in the minute. Then I left after 10 minutes I felt the same again for 2 minutes. I took my blood pressure but it was fine but my pulse was 95. I improved a little although the symptoms came and went. Already at 9 o'clock in the evening the dizziness and tachycardia disappeared. Today in the morning I felt a slight tachycardia but it went away when I took the 30mg cardizem.
Graves disease; shortness of breath; tachycardia; A spontaneous report was received from a health professional concerning a 49-years-old female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and had graves disease (basedow's disease), shortness of breath (dyspnoea), tachycardia  No medical history was provided. No concomitant medications were provided.  On 12 Feb 2021, the patient received the second of two planned doses of mRNA-1273 (Lot number: not provided), intramuscularly for prophylaxis of COVID-19 infection.  On 12 Feb 2021, the patient developed tachycardia and shortness of breath. On 13 Feb 2021, she had medical evaluation done that showed she did not have a pulmonary embolus. On 23 Feb 2021, lab data showed undetectable thyroid stimulating hormone (TSH). On 01 Mar 2021, she had full set of thyroid function tests that still showed an undetectable TSH and elevated free T4 and a total T3. She was confirmed to have Graves' disease (medically significant) based off elevated thyroid stimulating immunoglobulins.  The patient had been started on treatment.  The patient received both scheduled doses of mRNA-1273 prior to the event, therefore action taken with the drug in response to the event is not applicable.   The outcome of the events of graves disease (basedow's disease), shortness of breath (dyspnea), tachycardia was unknown.  The reporter assessed the events to be possibly related to the study drug.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Severe dizziness; Severe nausea; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO153) via an unspecified route of administration in the arm left on 06Apr2021 at 12:45 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient received other medicines (unspecified) within two weeks prior to the COVID-19 vaccine. The patient had allergies to medications, food or other products (unspecified). Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine.  On 06Apr2021 at 23:30, the patient experienced severe dizziness and severe nausea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events severe dizziness and severe nausea were unknown at the time of reporting.   No follow-up attempts are needed. No further information is expected.
5-10 mins after injection, the pt developed shortness of breath, pale, dizzy and pain at injection site and down right side. Given Ibuprofen and Benadryl. Then next day, cough, 2 days later fever, rash and increased cough.
my lymph node under my arm on the injection site arm are pretty swollen; whole site is more swollen; there is actually a small bump, tinier little bump for the actual injection site; it's very uncomfortable; booster; This is a spontaneous report from a contactable consumer, the patient. A 61-years-old patient of an unspecified gender received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: FH8028), via an unspecified route of administration, administered in Arm Left on 08Nov2021 at 14:15 as dose 3 (booster), single (at the age of 61-years-old) for covid-19 immunization. The patient medical history was not reported. Concomitant medications included ibuprofen, methocarbamol, erythromycin, isotretinoin (TRAXIN E). The patient previously took 2 doses of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, lot number: unknown), via an unspecified route of administration, on an unspecified date as dose 1, single and as dose 2, single for covid-19 immunization. It was reported that the patient had an unusual symptom that patient have not had till had the booster and patient did not have this symptom before. Patient having more actually, had little more symptoms which patient understand was not a bad thing but on 10Nov2021, one of thing was lymph node under arm on the injection site arm were pretty swollen. There was actually a small bump, tinier little bump for the actual injection site and it was very uncomfortable. Patient noticed this afternoon, so in last few hours and it was very uncomfortable. The patient did not receive any treatment for the events. The patient underwent lab tests and procedures which included laboratory test: unknown results on 25Oct2021. The outcome of the events was not recovered.  Follow-up attempts were completed. No further information was expected.
Described a large local reaction after receiving his second anthrax vaccine dose (from shoulder to below elbow. Went on sick call and was told it was normal. No numbness or tingling. Swelling and redness noted within first 24 hours after vaccine receipt and resolved within 5 days. Pain was rated as 2/10 using pain scale of 0 (=no pain) and 10 (=worst pain ever experienced).
Fever for 20 hours, acetaminophen Myalgias for 48 hours, acetaminophen headache for 24 hours, acetaminophen chills for 24 hours, acetaminophen tenderness at injection site for 48 hours, acetaminophen
Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Severe, Site: Swelling at Injection Site-Severe, Additional Details: Patient reported swelling and redness of arm after vaccine adminstration.  Swelling progressed to the size of "half a lemon" before seeking treatment in emergency department. Pt was prescribed antibiotic and symptoms have resolved.
adult received first dose of Havrix pediatric formulation by error; adult received first dose of Havrix pediatric formulation; This case was reported by a other health professional via call center representative and described the occurrence of accidental underdose in a 56-year-old male patient who received HAV (Havrix pediatric) (batch number 3HR79, expiry date 16th September 2021) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 20th August 2021, the patient received the 1st dose of Havrix pediatric and Havrix Pre-Filled Syringe Device. On 20th August 2021, unknown after receiving Havrix pediatric and Havrix Pre-Filled Syringe Device, the patient experienced accidental underdose and adult use of a child product. On an unknown date, the outcome of the accidental underdose and adult use of a child product were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: Medical assistant reported that an adult patient received a dose of Havrix pediatric formulation by error, which led to accidental underdose and adult use of a child product. The reporter consented to follow up via email.
I got the booster shot on my left arm and the next day i was hurting alot i couldnt even sleep so when i was in the shower i notice i have a big ball shape underneath my armpit that hurts alot i went to pharmacy and they told me my shot was given to low and they took pictures and said they will call me in 2 days